Aarti Pharmalabs Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Strong finish to a landmark year: Standalone EBITDA grew 23-24% YoY in FY25, with Q4 margins expanding to 26% from 23% a year ago, driven by operating leverage and efficiency.
• CDMO is the growth engine, but it will be lumpy: The segment added 6 new customers and 20 new products, and management guides for 30-40% revenue growth in FY26. However, large customers dictate supply timing, so quarterly revenue will be volatile, not linear.
• Xanthine has bottomed, capacity expansion is the next catalyst: Pricing is stable at low levels and has bottomed out. A 9,000 MT capacity expansion will begin coming online in H2 FY26, with full operationalization by Q1 FY27 and a 3-year ramp to 80-90% utilization.
• API growth is real but partner-dependent: The segment grew 28% in FY25 on the back of a few strong products and second-source opportunities. Future growth hinges on partners retaining market share and the success of upcoming patent-expiry launches.
• What to watch next quarter: The pace of Atali phase-I commercialization, any early revenue contribution from new Xanthine capacity, and whether the CDMO order book converts on schedule given its inherent lumpiness.

CDMO/CMO: The High-Growth, High-Volatility Engine

• Business model: Management positions Aarti as a "manufacturing specialist," targeting CMO opportunities around phase-3, where the success probability for small molecules exceeds 50% from phase-3 to final approval.
• Scale and composition: Currently working with 21 customers across 61 active projects, up from 56. Of these, 33 are at the commercial stage and 27 are under development. Phase-3 and commercialized products constitute 75-80% of overall CDMO sales value.
• Growth trajectory: The segment added roughly 20 new products and 6 new customers in the last year. Management guides for 30-40% revenue growth in FY26, with a large part of that already booked as orders in the system.
• The lumpiness caveat: Revenue was heavily skewed to H2 in FY25 (roughly 90% in H2) because large-volume customers dictate supply timing. Management was explicit that this volatility will persist and there will be no linearity in quarterly numbers going forward. Some products are campaigned only in alternate years.
• Margin profile: While management declined to give absolute margin differences across segments, they confirmed CDMO gross margins are "reasonably higher" than API and other businesses.
• Sustainability: Management stated that the large products which contributed this quarter will be sustainable, pushing back on the idea that CDMO revenue is inherently transient.

Rashesh Gogri: "We are specializing and pitching ourselves as a manufacturing specialist. We would like to pick up the projects for CMO opportunities in and around phase-3."

Xanthine Derivatives: Bottomed-Out Pricing, Capacity-Led Growth Ahead

• Pricing stability: Xanthine derivative prices are stable, low, but have bottomed out. Pharmaceutical-market pricing is higher due to FDA and medical agency communications. Low-end prices have bottomed out, while higher-end prices may come down a bit, creating a balance.
• Regulatory milestone achieved: The company completed filings for regulated approvals of USDMFs and CEP for the pharmaceutical market, as promised in the Q3 earnings call.
• Capacity expansion timeline: New capacity will begin coming online in H2 FY26, with some volumes in November-December-January and more by March. Full operationalization is targeted by Q1 FY27.
• Utilization ambition: Over the next three years, management aspires to reach 80-90% capacity utilization, with 50% of sales targeted to beverages and regulated customers. The segment will grow in terms of overall quantum of revenue.
• Margin confidence: While spot prices are at the bottom, average realizations are healthier. Management is confident of growing EBITDA despite possible 1% margin volatility from product mix shifts.

Rashesh Gogri: "You know the margins may move 1% here or there, but I think we are quite confident that we will be able to grow the EBITDA."

API & Intermediates: Partner-Dependent Growth with a Patent-Expiry Pipeline

• FY25 performance: The segment delivered its highest-ever quarterly sales and grew 28% for the full year, driven by a few strong products. Growth came from regulated markets and export-backed markets, including domestic sales where the end-customer ultimately exports to regulated markets.
• The partner dependency: Management acknowledged that growth is contingent on partners retaining market share and on second-source opportunities where Aarti's backward integration provides an edge. No product is currently under threat, but the company declined to extrapolate FY25 growth into FY26 for this segment.
• Patent-expiry pipeline: Over the next 3-5 years, many molecules will go off-patent. Aarti has 8-10 APIs under development and more than 50 DMFs already filed to capture generic market share. For large products where integrated players win, backward integration gives Aarti additional market share.
• New launches ahead: A few new API launches are coming in the next couple of years, including anti-diabetic and anti-cancer products. The company develops 20-25 new products every year across categories.
• Capacity addition: At Tarapur Unit-4, one additional line will increase capacity by 15-20%. Plans are also underway to enhance capacities for steroids and anti-cancer products.

Atali Greenfield & Capacity Expansion

• Atali phase-I: The greenfield project is in final stages of completion, with mechanical closure expected around the end of Q1 FY26. After that, regulatory approvals and customer audits will take time. Full ramp-up is expected by the end of FY26. Phase-I will not add meaningful revenue or contribution in the initial phase; expenses will start adding up in H2 FY26.
• Xanthine capacity: 9,000 MT expansion will be fully operationalized by Q1 FY27, with a gradual ramp to over 90% utilization across three years.
• API capacity: A 15-20% capacity increase at Tarapur Unit-4, plus plans for steroid and anti-cancer product capacity.
• Ganesh Polychem: A 3-4 month shutdown for a lower-cost production route upgrade impacted Q4 and will impact Q1 FY26. Once complete, the site will be a competitive source. Management is also doubling capacity for an aerospace-application product used in jets and drones.

Rashesh Gogri: "So that product we are trying to expand our volume and that also will happen in coming year where we are doubling the capacity from earlier year. With that, I think a couple of quarters of pain, but ultimately overall in future it looks sound."

Margins, Capital Allocation & Subsidiary Performance

• EBITDA margin expansion: Margins expanded to 26% in Q4 FY25 from 23% in Q4 FY24, driven by operating leverage and efficiency measures. PAT growth was supported by both topline growth and margin expansion.
• FY26 EBITDA guidance: Management guides for 12-15% standalone EBITDA growth over the higher base of FY25, supported by an increasing contribution from higher-margin products, improved process efficiencies, and volume growth. When pressed on whether this should be higher given 30%+ CDMO growth, management deflected, saying the base is significantly high and investors should be happy with good growth.
• Borrowings: Expected to increase by ₹100-125 crores in FY26, keeping debt-equity at approximately 0.23 to 0.25.
• Capex breakup: Investments span Atali, solar, Xanthine capacity, and R&D. The solar plant has a payback period of 3.5-4 years.
• Aarti USA: The business is decreasing, with Q4 topline at roughly ₹7 crores. It is not being wound up but is declining.
• Ganesh Polychem: EBITDA fell significantly due to a demand slowdown and the 3-4 month site shutdown. After the upgrade, management expects to recover lost ground and gain market share.
• Other income: Was negative in Q4 due to forex losses from rupee/dollar movement during the quarter.

Rashesh Gogri: "Currently, we are on significantly high base of FY25 because we have grown over last year by almost 23%-24% on EBITDA. So, over and above, I think we should be happy with the good growth."

New Capabilities & Strategic Initiatives

• Peptide manufacturing: The company has started attempting mid-size peptides and has a few projects in the pipeline. It will eventually do more solid-phase products. Entry into weight-loss drugs is still in the pipeline, not yet in the product portfolio.
• Sustainability milestones: Aarti earned an EcoVadis Gold Rating, ranking among the top 5% globally. Its GHG emission reduction targets were approved by SBTi, making it the sixth Indian pharma CDMO player to earn SBTi approval for all three scopes.
• Promoter selling: Some selling by promoter groups has occurred. Management expects minor selling here and there but no large change in promoter holding or control.

Rashesh Gogri: "Different promoter groups have different appetite to and long term plans. So I think there will be minor selling here or there, but it will not affect overall control of the company or anything."

Guidance & Commitments

Key Metrics